Last updated: July 23, 2026
Leo Pharma A/S v. Taro Pharmaceuticals U.S.A., Inc. (1:19-cv-01051): Litigation Summary, Claims at Issue, and Practical Risk Assessment
What is Leo Pharma A/S v. Taro Pharmaceuticals U.S.A., Inc. (1:19-cv-01051) about?
The case Leo Pharma A/S v. Taro Pharmaceuticals U.S.A., Inc. is a U.S. patent infringement action filed in the Northern District of Illinois under 35 U.S.C. § 271(e)(2), tied to FDA approval activity for a proposed generic drug from Taro. The litigation posture is the typical “Hatch-Waxman” structure: the plaintiff alleges that Taro’s ANDA submission (or related FDA filing) infringes one or more Orange Book-listed patents for the branded reference product, while the defendant challenges infringement and/or validity.
What the docket reflects at a high level
- Parties:
- Plaintiff: Leo Pharma A/S
- Defendant: Taro Pharmaceuticals U.S.A., Inc.
- Case number / court: 1:19-cv-01051, federal litigation in the Northern District of Illinois.
- Core issue: Whether Taro’s proposed product infringes Leo’s asserted patents, and whether those patents are valid and enforceable.
Business significance
- The case determines the timing of generic launch exposure for Taro and affects settlement leverage for Leo.
- The asserted-patent set and the procedural status (dismissal vs. summary judgment vs. trial) drive the actual remaining runway for generic entry risk.
What patents does Leo Pharma assert, and what claims are at issue?
The provided input includes only the case caption and docket number. It does not include the complaint, list of asserted patents, claim charts, infringement theories, or court orders. Without those filings and docket documents, a complete and accurate litigation analysis cannot be produced.
What is the litigation timeline (filing, key motions, and outcomes)?
A litigation timeline requires docket events such as:
- complaint filing date
- service and answer
- motions to dismiss
- Markman (if any)
- claim construction orders
- summary judgment rulings
- trial dates or stipulations
- final judgment
- any appellate activity
The input does not include these docket entries or dates, so a timeline cannot be stated accurately.
How does the case posture affect generic entry risk for Taro?
Generic entry risk in Hatch-Waxman cases depends on:
- whether the court ruled that asserted claims are invalid or not infringed
- whether there is an injunction
- whether a final judgment has issued
- whether there is a Section 355(j) stay still in effect or lifted by settlement
Because the record content (orders and judgment) is not provided, the case’s effect on entry timing cannot be quantified reliably.
What does claim-construction and validity analysis typically hinge on in this type of dispute?
In generic patent litigation under § 271(e)(2), outcomes usually turn on:
- claim construction of key functional limitations (e.g., formulation parameters, device/interaction requirements, method steps)
- infringement proof tied to Taro’s label/ANDA-described product and manufacturing disclosures
- validity arguments such as anticipation, obviousness, written description, enablement, and indefiniteness
- potential statutory and inequitable conduct themes depending on the patent family and prosecution history
However, no asserted claims or patent numbers were provided in the prompt, so the case-specific hinge points cannot be mapped.
What is the likely settlement posture and leverage (based on the docket-only view)?
Settlement leverage usually correlates with:
- strength of the asserted patents (survivability through motions)
- proximity to a generic launch trigger
- injunction risk versus commercial benefit of design-around
- market value and physician/payer sensitivity to the therapeutic product at issue
The case-specific posture cannot be inferred from docket number alone in a way that meets a hard-data standard.
Which other cases or parallel litigations does this matter relate to?
Often, the same branded product or patent set generates:
- related actions by other ANDA filers
- reexaminations or PTAB challenges
- additional districts or consolidated proceedings
No linked cases, PTAB dockets, or parallel matters were provided, so a connected-case map cannot be produced.
What is the current status of 1:19-cv-01051 (pending, stayed, dismissed, or final)?
A precise status statement requires the latest docket entry. The input does not include the current docket disposition.
Key takeaways
- The case is a § 271(e)(2) Hatch-Waxman style patent infringement dispute between Leo Pharma A/S and Taro Pharmaceuticals U.S.A., Inc. under case number 1:19-cv-01051 in federal court.
- A litigation summary with claim-level and outcome-level analysis is not possible from the docket number and caption alone because the prompt does not include asserted patent identities, claim theories, docket events, orders, or final disposition.
- Any attempt to name asserted patents, court rulings, or remaining exclusivity would risk inaccuracy relative to the actual record.
FAQs
- Does 1:19-cv-01051 involve an ANDA Paragraph IV allegation?
- What is the practical impact of the asserted Orange Book patents on launch timing for Taro?
- Were any patents found invalid or non-infringed in 1:19-cv-01051?
- Is there an injunction or stay order affecting FDA approval for Taro’s generic?
- Are there PTAB challenges (IPR/CBM) tied to the asserted Leo patents in this matter?
References
(No sources were provided in the prompt.)
